Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Financing Activities (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Cash from Financing Activities for 3 consecutive years, with $352000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities changed N/A to $352000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $100.2 million, a 38.12% increase, with the full-year FY2024 number at $71.7 million, down 64.51% from a year prior.
  • Cash from Financing Activities was $352000.0 for Q3 2025 at Inhibrx Biosciences, down from $99.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $199.9 million in Q3 2023 to a low of $352000.0 in Q3 2025.
  • A 3-year average of $62.1 million and a median of $35.8 million in 2024 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 157.8% in 2025; the steepest drop was 157.8% in 2025.
  • Inhibrx Biosciences' Cash from Financing Activities stood at $860000.0 in 2023, then skyrocketed by 3731.4% to $32.9 million in 2024, then plummeted by 98.93% to $352000.0 in 2025.
  • Per Business Quant, the three most recent readings for INBX's Cash from Financing Activities are $352000.0 (Q3 2025), $99.8 million (Q1 2025), and $32.9 million (Q2 2024).